| Literature DB >> 20589071 |
Abstract
The use of antimicrobial agents in the veterinary field affects the emergence, prevalence, and dissemination of antimicrobial resistance in bacteria isolated from food-producing animals. To control the emergence, prevalence, and dissemination of antimicrobial resistance, it is necessary to implement appropriate actions based on scientific evidence. In Japan, the Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) was established in 1999 to monitor the antimicrobial susceptibility of foodborne and commensal bacteria from food-producing animals. The JVARM showed that the emergence and prevalence of resistant Escherichia coli were likely linked to the therapeutic antimicrobial use in food-producing animals through not only direct selection of the corresponding resistance but also indirect selections via cross-resistance and coresistance. In addition, relevant factors such as host animals and bacterial properties might affect the occurrence and prevalence of antimicrobial-resistant E. coli under the selective pressure from antimicrobial usage. This paper reviews the trends in antimicrobial resistance in E. coli and consumption of antimicrobials agents in Japan and introduces the relationship between antimicrobial usage and prevalence of antimicrobial-resistant bacteria, from food-producing animals under the JVARM program. In this paper, we will provide the underlying information about the significant factors that can help control antimicrobial resistance in bacteria in veterinary medicine.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20589071 PMCID: PMC2879543 DOI: 10.1155/2010/180682
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
Figure 1Trends in veterinary antimicrobials sold from pharmacies in Japan.
Figure 2Trends in assay acceptable amounts of antimicrobial feed additives in Japan.
Figure 3Trends in resistance to selected antimicrobials among commensal E. coli isolates from cattle, pigs, and broiler chickens in Japan.
Figure 4Relative risks of antimicrobial resistance in porcine E. coli isolates due to exposure to antimicrobials mainly used in Japan. aSymbols indicate the values of relative risk of each resistance due to exposure to tetracycline antibiotics (), penicillin antibiotics (▴), methoprims-sulfonamides combination drugs (◆), and penicillin-streptomycin combination drugs (■). *In case that 95% confidence interval () does not include the value 1, the relative risk is considered statistically significant (P < .05). This figure is based on the data obtained from the previous manuscript mentioned in [42].
(a) Current trends in rates (%) of resistance to selected antimicrobials in commensal E. coli isolates from cattle
| Country | Survey year | PCa | SMb | TCc | FQd | References |
|---|---|---|---|---|---|---|
| Japane | 2007 | 9.2 | 19.2 | 26.2 | 1.5 | [ |
| United Statesf | 2002-2003 | 2.5 | 10.2 | 23.1 | NT | [ |
| Canada | 2005 | 2.5 | 7.4 | 22.1 | 0.0 | [ |
| Denmark | 2006 | 2.2 | 10.8 | 9.7 | 0.0 | [ |
| France | 2004 | 14.0 | 20.0 | 26.0 | 0.0 | [ |
| Norway | 2005 | 2.0 | 9.2 | 1.0 | 0.0 | [ |
| Sweden | 2006 | 0.0 | 2.0 | 2.0 | <1.0 | [ |
| UKf | 2004 | 3.0 | 2.0 | 6.0 | NT | [ |
| Netherlands | 2005 | 48.5 | NT | 82.4 | 25.5 | [ |
| Finland | 2006 | <1.0 | 3.0 | <1.0 | 1.0 | [ |
| Italy | 1999–2001 | 14.3 | 15.3 | 19.6 | 2.1 | [ |
| Germany | 1999–2001 | 1.7 | 3.7 | 6.5 | 0.0 | [ |
| Australia | 2003-2004 | 0.0 | NT | 3.0 | 0.0 | [ |
| Koreaf | 2003-2004 | 12.0 | 20.4 | 30.5 | 0.6 | [ |
aPC, penicillin antibiotics including ampicillin (MIC breakpoints, 16–32 mg/L) and amoxicillin (16 mg/L).
bSM, streptomycin antibiotics including streptomycin (16–64 mg/L) and dihydrostreptomycin (32 mg/L).
cTC, tetracycline antibiotics including tetracycline and oxytetracycline (16 mg/L).
dFQ, fluoroquinolone agents including ciprofloxacin (0.125–4 mg/L) and enrofloxacin (0.125–2 mg/L). In particular, some European countries like Denmark, Norway, Sweden, Netherlands, and Finland adopted low MIC breakpoints between 0.125 and 1.0 mg/L.
eIn Japan, ampicillin, dihydrostreptomycin, oxytetracycline, and enrofloxacin were used as the representative of PC, SM, TC, and FQ, respectively, for susceptibility testing. As for ampicillin, the MIC breakpoint established by the Clinical Laboratory Standards Institute was adopted (32 mg/L) [33]; for the remaining antimicrobials, MIC breakpoints were set as the midpoint between the peaks of each MIC distribution (dihydrostreptomycin, 32 mg/L; oxytetracycline, 16 mg/L; enrofloxacin, 2 mg/L) [34].
fSusceptibility tests for all antimicrobials were performed by disk diffusion method.
(b) Current trends in rates (%) of resistance to selected antimicrobials in commensal E. coli isolates from pigs
| Country | Survey year | PCa | SMb | TCc | FQd | References |
|---|---|---|---|---|---|---|
| Japane | 2007 | 22.6 | 43.4 | 57.5 | 0.0 | [ |
| United Statesf | 2002-2003 | 18.8 | 30.6 | 63.1 | NT | [ |
| Canada | 2005 | 34.6 | 38.9 | 74.7 | 0.6 | [ |
| Denmark | 2006 | 20.3 | 40.5 | 28.4 | 0.7 | [ |
| France | 2004 | 22.0 | 62.0 | 86.0 | 1.0 | [ |
| Norway | 2004 | 8.0 | 33.6 | 9.6 | 0.0 | [ |
| Sweden | 2005 | 6.0 | 14.0 | 9.0 | <1.0 | [ |
| UKf | 2004 | 28.0 | 28.0 | 80.0 | NT | [ |
| Netherlands | 2005 | 30.4 | NT | 61.9 | 0.0 | [ |
| Spainf | 2005 | 60.9 | 63.5 | 90.1 | 4.2 | [ |
| Australia | 2003-2004 | 35.0 | NT | 76.0 | 0.0 | [ |
| Korea | 2001–2003 | 75.2 | 85.7 | 99.2 | 7.5 | [ |
| Chile | 2003 | NT | 84.0 | 96.0 | 6.0 | [ |
aPC, penicillin antibiotics including ampicillin (MIC breakpoints, 16–32 mg/L) and amoxicillin (16–32 mg/L).
bSM, streptomycin antibiotics including streptomycin (16–64 mg/L) and dihydrostreptomycin (32 mg/L).
cTC, tetracycline antibiotics including tetracycline and oxytetracycline (16 mg/L).
dFQ, fluoroquinolone agents including ciprofloxacin (0.125–4 mg/L) and enrofloxacin (0.125–2 mg/L). In particular, some European countries like Denmark, Norway, Sweden, and Netherlands adopted low MIC breakpoints between 0.125 and 1.0 mg/L.
eIn Japan, ampicillin, dihydrostreptomycin, oxytetracycline, and enrofloxacin were used as the representative of PC, SM, TC, and FQ, respectively, for susceptibility testing. As for ampicillin, the MIC breakpoint established by the Clinical Laboratory Standards Institute was adopted (32 mg/L) [33]; for the remaining antimicrobials, MIC breakpoints were set as the midpoint between the peaks of each MIC distribution (dihydrostreptomycin, 32 mg/L; oxytetracycline, 16 mg/L; enrofloxacin, 2 mg/L) [34].
fSusceptibility tests for all antimicrobials (the United States and UK) or streptomycin (Spain) were performed by disk diffusion method.
(c) Current trends in rates (%) of resistance to selected antimicrobials in commensal E. coli isolates from broilers
| Country | Survey year | PCa | SMb | TCc | FQd | References |
|---|---|---|---|---|---|---|
| Japane | 2007 | 42.2 | 43.1 | 53.9 | 5.9 | [ |
| United Statesf | 2002-2003 | 2.1 | 15.1 | 35.1 | NT | [ |
| Canada | 2005 | 38.5 | 43.1 | 57.3 | 0.0 | [ |
| Denmark | 2006 | 17.1 | 10.6 | 6.5 | 5.7 | [ |
| France | 2004 | 37.0 | 39.0 | 73.0 | 4.0 | [ |
| Norway | 2006 | 13.2 | 2.1 | 3.7 | 1.1 | [ |
| Sweden | 2004 | 4.0 | 6.0 | 6.0 | 2.0 | [ |
| UKf | 2004 | 37.0 | NT | 65.0 | 6.0 | [ |
| Netherlands | 2005 | 63.5 | NT | 60.9 | 50.8 | [ |
| Spainf | 2005 | 64.0 | 51.0 | 68.0 | 53.0 | [ |
| Finland | 2005 | 16.0 | 7.0 | 17.0 | 1.0 | [ |
| Australia | 2003-2004 | 33.0 | NT | 44.0 | 0.4 | [ |
| Korea | 2001–2003 | 63.8 | 86.5 | 80.4 | 50.1 | [ |
| Chile | 2003 | NT | 57.1 | 80.6 | 28.5 | [ |
aPC, penicillin antibiotics including ampicillin (MIC breakpoints, 16–32 mg/L) and amoxicillin (16–32 mg/L).
bSM, streptomycin antibiotics including streptomycin (16–64 mg/L) and dihydrostreptomycin (32 mg/L).
cTC, tetracycline antibiotics including tetracycline and oxytetracycline (16 mg/L).
dFQ, fluoroquinolone agents including ciprofloxacin (0.125–4 mg/L) and enrofloxacin (0.125–2 mg/L). In particular, some European countries like Denmark, Norway, Sweden, Netherlands, and Finland adopted low MIC breakpoints between 0.125 and 1.0 mg/L.
eIn Japan, ampicillin, dihydrostreptomycin, oxytetracycline, and enrofloxacin were used as the representative of PC, SM, TC, and FQ, respectively, for susceptibility testing. As for ampicillin, the MIC breakpoint established by the Clinical Laboratory Standards Institute was adopted (32 mg/L) [33]; for the remaining antimicrobials, MIC breakpoints were set as the midpoint between the peaks of each MIC distribution (dihydrostreptomycin, 32 mg/L; oxytetracycline, 16 mg/L; enrofloxacin, 2 mg/L) [34].
fSusceptibility tests for all antimicrobials (the United States and UK) or streptomycin (Spain) were performed by disk diffusion method.